Cardiac troponin testing in the management of patients infected with Sars-Cov-2

Coronavirus disease 2019 (COVID-19) is a viral zoonosis caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). High sensitive Troponin cardiac (hs-cTn) is a biomarker frequently measured during the management of COVID-19. We conducted a descriptive retrospective study at the Paraclinical Service of Training and Researches in Biochemistry at the University Hospital Center of Joseph Ravoahangy Andrianavalona Madagascar over a period of five months. Our objective was to describe the modalities and the relevance of the prescription of hs-cTn determination within the intensive care units of the hospital. Of the 42 patient files collected in our work, we found a slight male predominance (sex ratio = 1.47) and the average age was 56.8 years. In 18 patients, hs-cTn was positive and among the 19 patients who died as a result of their disease 11 had elevated plasma troponin levels. During COVID 19, troponin assay should be prescribed appropriately to enhance the management of patients in a developing country like Madagascar where the cost of assaying this biomarker remains high.